MedTrace Logo

Evaluation of Platelet-rich Fibrin for Revascularization of Immature Permanent Teeth Versus Standard Apexification

NCT06693349 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-11-18

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the effect of platelet-rich fibrin for revascularization of immature permanent teeth in comparison to standard apexification using calcium hydroxide (as a 12 months follow up for previous study) through using clinical outcomes and radiographically using cone beam computed tomography the main questions it aims to answer are

* is the platelet-rich fibrin an effective mean for management of necrotic immature permanent teeth
* is the platelet-rich fibrin has a superior clinical and radiographic effects than calcium hydroxide apexification participants were treated either by platelet-rich fibrin revascularisation or calcium hydroxide apexification

Conditions

  • To Evaluate the Clinical and Radiographic Effect of Platelet-rich Fibrin in Treatment of Necrotic Permanent Teeth with Open Apices

Interventions

DRUG

the effect of platelet-rich fibrin in treatment of contaminated and uncontaminated immature permanent teeth

this procedure was anticipated to give superior effects than other procedure used in this study

DRUG

the effect of apexification in treatment of contaminated and uncontaminated immature permanent teeth

this procedure was anticipated to be replaced by other procedure be used in this study

Sponsors & Collaborators

  • Mansoura University

    collaborator OTHER

  • Mohammed Nasser Alhajj

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-02
Primary Completion
2021-02-20
Completion
2021-04-12

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06693349 on ClinicalTrials.gov